STAT+: The old Vinay Prasad never left. He just changed jobs
Stat News • 2/12/2026
Summary
Vinay Prasad changed jobs, but his conservative regulatory doctrine remains unchanged, especially regarding cell and gene therapies. The approval bar for these therapies is now much higher.
Advertisement
Lindy Score Breakdown (V4.2)
51d
Age
1
Sources
from cluster
1219
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1219/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1219/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 50 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: ‘Takeover Tuesday’ saves biotech’s quarter
Stat News • 1 day ago
STAT+: Makary marks one year at FDA with focus on achievements in speech to staff
Stat News • 2 days ago
STAT+: Large AI scribe study finds modest time savings, inconsistent use
Stat News • 2 days ago
STAT+: Proposed ‘preclinical obesity’ diagnosis ignites global debate among experts
Stat News • 1 day ago
STAT+: Pharmalittle: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more
Stat News • 2 days ago
STAT+: Insilico Medicine CEO on how best to use AI in drug development
Stat News • 2 days ago
STAT+: Novo’s subscription model raises questions about pharma-telehealth tie-ups
Stat News • 2 days ago
STAT+: Government watchdog urges FDA to finalize guidance for advisory committee conflicts of interest
Stat News • 2 days ago
STAT+: Trump announces 100% tariffs on brand-name drugs, with plenty of carveouts
Stat News • 1 day ago
STAT+: FDA’s evolving view of what makes a ‘breakthrough’ device
Stat News • 1 day ago
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago